Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression

Cancer Letters

Volumn 355, Issue 1, 2014, Pages 61-69

  Kim, Hye Young ^a   Jung, Hye Uk ^a   Yoo, Seung Hee ^a   Yoo, Ki Soo ^a   Cheong, JaeHun ^b   Park, Bong Soo ^b   Yun, Il ^b   Yoo, Young Hyun ^a  

^a Dong A University College of Medicine   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

Apoptosis; HBx protein; HCC; Hepatitis B virus; Sorafenib

Indexed keywords

ALPHA INTERFERON; HEPATITIS B VIRUS X PROTEIN; PROTEASOME; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CISPLATIN; ETOPOSIDE; NICOTINAMIDE; TRANSACTIVATOR PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER RESISTANCE; CELL FUNCTION; CELL PROTECTION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; GENE REPRESSION; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA CELL LINE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; SENSITIVITY ANALYSIS; UPREGULATION; VIRUS GENE; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PROMOTER REGION; VIROLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, VIRAL; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; TRANS-ACTIVATORS; TRANSFECTION;

EID: 84908000708     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.015     Document Type: Article

References (41)

1. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
2. Wei Y., Neuveut C., Tiollais P., Buendia M.A. Molecular biology of the hepatitis B virus and role of the X gene. Pathol. Biol. (Paris) 2010, 58:267-272.
3. Neuveut C., Wei Y., Buendia M.A. Mechanisms of HBV-related hepatocarcinogenesis. J. Hepatol 2010, 52:594-604.
4. Motavaf M., Safari S., Saffari Jourshari M., Alavian S.M. Hepatitis B virus-induced hepatocellular carcinoma: the role of the virus × protein. Acta Virol 2013, 57:389-396.
5. Rawat S., Clippinger A.J., Bouchard M.J. Modulation of apoptotic signaling by the hepatitis B virus X protein. Viruses 2012, 4:2945-2972.
6. Xu C., Zhou W., Wang Y., Qiao L. Hepatitis B virus-induced hepatocellular carcinoma. Cancer Lett 2014, 345:216-222.
7. Tang H., Oishi N., Kaneko S., Murakami S. Molecular functions and biological roles of hepatitis B virus × protein. Cancer Sci 2006, 97:977-983.
8. Ng S.A., Lee C. Hepatitis B virus X gene and hepatocarcinogenesis. J. Gastroenterol 2011, 46:974-990.
9. Kew M.C. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J. Gastroenterol. Hepatol 2011, 26(Suppl. 1):144-152.
10. Wang W.H., Hullinger R.L., Andrisani O.M. Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis. J. Biol. Chem 2008, 283:25455-25467.
11. Chung T.W., Lee Y.C., Kim C.H. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J. 2004, 18:1123-1125.
12. Cheng A.S., Wong N., Tse A.M., Chan K.Y., Chan K.K., Sung J.J., et al. RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma. Cancer Lett 2007, 253:43-52.
13. Zhang C.Z., Zhang H.T., Chen G.G., Lai P.B. Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment. Apoptosis 2011, 16:683-695.
14. Doria A., Gatto M., Punzi L. Autophagy in human health and disease. N. Engl. J. Med 2013, 368:1845.
15. Rautou P., Mansouri A., Lebrec D., Durand F., Valla D., Moreau R. Autophagy in liver diseases. J. Hepatol 2010, 53:1123-1134.
16. Chen S., Rehman S.K., Zhang W., Wen A., Yao L., Zhang J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim. Biophys. Acta (BBA)-Rev. Cancer 2010, 1806:220-229.
17. Janku F., McConkey D.J., Hong D.S., Kurzrock R. Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol 2011, 8:528-539.
18. Tang H., Da L., Mao Y., et al. Hepatitis B virus X protein sensitizes cells to starvation-induced autophagy via up-regulation of beclin 1 expression. Hepatology 2009, 49:60-71.
19. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
20. Wang X.W., Gibson M.K., Vermeulen W., Yeh H., Forrester K., Sturzbecher H.W., et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995, 55:6012-6016.
21. Zhu H., Luo S.F., Wang J., Li X., Wang H., Pu W.Y., et al. Effect of environmental factors on chemoresistance of HepG2 cells by regulating hypoxia-inducible factor-1alpha. Chin. Med. J. (Engl.) 2012, 125:1095-1103.
22. Cheng A.S., Yu J., Lai P.B., Chan H.L., Sung J.J. COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis,. Biochem. Biophys. Res. Commun 2008, 374:175-180.
23. Townsend K.N., Hughson L.R., Schlie K., Poon V.I., Westerback A., Lum J.J. Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. Immunol. Rev 2012, 249:176-194.
24. Gong D.Y., Chen E.Q., Huang F.J., Leng X.H., Cheng X., Tang H. Role and functional domain of hepatitis B virus X protein in regulating HBV transcription and replication in vitro and in vivo. Viruses 2013, 5:1261-1271.
25. Gearhart T.L., Bouchard M.J. The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J. Virol 2010, 84:2675-2686.
26. Himmelsbach K., Sauter D., Baumert T.F., Ludwig L., Blum H.E., Hildt E. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 2009, 58:1644-1653.
27. Asselah T., Lada O., Moucari R., Martinot M., Boyer N., Marcellin P. Interferon therapy for chronic hepatitis B. Clin. Liver Dis 2007, 11:839-849. viii.
28. Liu Y., Lou G., Wu W., Shi Y., Zheng M., Chen Z. Interferon-alpha sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-kappaB activation. Virol. J. 2013, 10. 168-422X-10-168.
29. Nowak A.K., Chow P.K., Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur. J. Cancer 2004, 40:1474-1484.
30. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
31. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
32. Cheng A.L., Guan Z., Chen Z., et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur. J. Cancer 2012, 48:1452-1465.
33. Yoo S.H., Yoon Y.G., Lee J.S., Song Y.S., Oh J.S., Park B.S., et al. Etoposide induces a mixed type of programmed cell death and overcomes the resistance conferred by bcl-2 in Hep3B hepatoma cells. Int. J. Oncol 2012, 41:1443-1454.
34. Pan J., Duan L.X., Sun B.S., Feitelson M.A. Hepatitis B virus X protein protects against anti-fas-mediated apoptosis in human liver cells by inducing NF-kappa B. J. Gen. Virol 2001, 82:171-182.
35. Lee Y.I., Kang-Park S., Do S.I., Lee Y.I. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J. Biol. Chem 2001, 276:16969-16977.
36. Shih W.L., Kuo M.L., Chuang S.E., Cheng A.L., Doong S.L. Hepatitis B virus X protein inhibits transforming growth factor-beta -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J. Biol. Chem 2000, 275:25858-25864.
37. Kuo T.C., Chao C.C. Hepatitis B virus X protein prevents apoptosis of hepatocellular carcinoma cells by upregulating SATB1 and HURP expression. Biochem. Pharmacol 2010, 80:1093-1102.
38. Sir D., Tian Y., Chen W.L., Ann D.K., Yen T.S., Ou J.H. The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. Proc. Natl Acad. Sci. U.S.A. 2010, 107:4383-4388.
39. Mao Y., Da L., Tang H., Yang J., Lei Y., Tiollais P., et al. Hepatitis B virus X protein reduces starvation-induced cell death through activation of autophagy and inhibition of mitochondrial apoptotic pathway. Biochem. Biophys. Res. Commun 2011, 415:68-74.
40. Schek N., Bartenschlager R., Kuhn C., Schaller H. Phosphorylation and rapid turnover of hepatitis B virus X-protein expressed in HepG2 cells from a recombinant vaccinia virus. Oncogene 1991, 6:1735-1744.
41. Kim J.H., Sohn S.Y., Benedict Yen T.S., Ahn B.Y. Ubiquitin-dependent and -independent proteasomal degradation of hepatitis B virus X protein. Biochem. Biophys. Res. Commun 2008, 366:1036-1042.